We ’ re very

“ proud of this continued growth this change , Resilience believes that the driving force has to come from the outside . “ Major pharmaceutical companies aren ’ t afforded the time to develop new manufacturing platforms ,” Rahul argues . “ Regulatory pathways are fast , and if drugs are proven to work , timelines can be shrunk down to between three or four years . At Resilience , we ’ re decoupling these two activities , focusing on developing the platforms that can then be supplied to companies from the get-go , for them to produce scalable , low-cost , high-yield products . “ In many cases within drugs and medicines manufacturing , what drives overall cost is both the cost of goods , and the cost of development ,” he elaborates . “ If we can develop better platforms that are able to reduce both those costs , then it creates an opportunity to reduce the price of the drug itself . If we can achieve that , then the drug will immediately become more accessible . Of course , we have to work within the system to make that happen ; we can ’ t set the price of drugs , because we ’ re not a drugs manufacturer . However , we ’ re providing the basis for a price reduction to take place .”

“

We ’ re very

“ proud of this continued growth this change , Resilience believes that the driving force has to come from the outside . “ Major pharmaceutical companies aren ’ t afforded the time to develop new manufacturing platforms ,” Rahul argues . “ Regulatory pathways are fast , and if drugs are proven to work , timelines can be shrunk down to between three or four years . At Resilience , we ’ re decoupling these two activities , focusing on developing the platforms that can then be supplied to companies from the get-go , for them to produce scalable , low-cost , high-yield products . “ In many cases within drugs and medicines manufacturing , what drives overall cost is both the cost of goods , and the cost of development ,” he elaborates . “ If we can develop better platforms that are able to reduce both those costs , then it creates an opportunity to reduce the price of the drug itself . If we can achieve that , then the drug will immediately become more accessible . Of course , we have to work within the system to make that happen ; we can ’ t set the price of drugs , because we ’ re not a drugs manufacturer . However , we ’ re providing the basis for a price reduction to take place .”